AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash.

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company, for up ...

Capstan brings a new modality to AbbVie’s immunology pipeline. The most advanced Capstan program is CPTX2309, which is being developed as a treatment for B cell-mediated autoimmune disorders.

A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the ...